Related Experiment Video

Updated: Aug 5, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Remarkable response to chidamide plus rituximab in an elderly patient with recurrent, chemotherapy-refractory diffuse

Dongdong Zhang1, Yidi Han2, Youhong Dong2

  • 1Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China. zhangdongdong@whu.edu.cn.

Annals of Hematology
|March 29, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Related Experiment Videos

Last Updated: Aug 5, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

Articles linked to this work by shared authors, journal, and citation graph.

Prospective Multicenter Observational Study of Anlotinib in Advanced Non-Small Cell Lung Cancer: Real-World Evidence From China.

Thoracic cancer·2026

Protein quality control and antigen presentation in the development of hepatitis B-related hepatocellular carcinoma.

Frontiers in pharmacology·2026

Novel SNX25-ROS1 fusion mutation confers therapeutic sensitivity to entrectinib: a case report and literature review.

Journal of chemotherapy (Florence, Italy)·2025

Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway.

PloS one·2025

Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.

BMC cancer·2025

Synchronous multiple primary cancers involving cervical cancer and follicular lymphoma: A case report.

Oncology letters·2025

Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma.

Annals of hematology·2026

Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature.

Annals of hematology·2026

Obstetric and thrombotic outcomes among pregnant patients with myeloproliferative neoplasms: a propensity score matched real-world analysis.

Annals of hematology·2026

Primary central nervous system lymphoma in the molecular era: genomic drivers, liquid biopsy, and targeted therapeutic strategies.

Annals of hematology·2026

The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model.

Annals of hematology·2026

Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association.

Annals of hematology·2026

Optimizing management strategies for T4b esophageal cancer: the role of TEVAR in multimodal treatment approaches.

Scandinavian journal of gastroenterology·2026

Prophylaxis Durations and Risks of Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study.

Transplant infectious disease : an official journal of the Transplantation Society·2026

Australian Practical Guide on the Management of Muscle-Invasive Bladder Cancer.

Asia-Pacific journal of clinical oncology·2026

[Efficacy of bidirectional switching therapy between adrenal ablation and adrenalectomy in patients with primary aldosteronism].

Zhonghua yi xue za zhi·2026

[Analysis of efficacy and prognostic factors of neoadjuvant chemoradiotherapy in locally advanced mid-low rectal cancer patients with RAS gene mutation].

Zhonghua yi xue za zhi·2026

[Expert consensus on co-ablation therapy for the perioperative management of bone and soft tissue tumors].

Zhonghua nei ke za zhi·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us